Azopt
| Azopt | |
|---|---|
| DOSAGE | 1 gtt TID |
| GENERIC | brinzolamide 1% |
| SIZE | 10 mL, 15mL |
| INDICATIONS | Reduction of elevated intraocular pressure (IOP) |
| MECHANISM OF ACTION | Decreases aqueous production |
| MICROBIOLOGY | Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. |
| CONTRAINDICATIONS & WARNINGS | Steven’s Johnson syndrome and sulfonamide hypersensitivity |
| PEDIATRIC USE | A 3-month controlled clinical study was conducted in which AZOPT was dosed only twice a day in pediatric patients 4 weeks to 5 years of age. Patients were not required to discontinue their IOP-lowering medication(s) until initiation of monotherapy with AZOPT. IOP-lowering efficacy was not demonstrated in this study in which the mean decrease in elevated IOP was between 0 mmHg and 2 mmHg. |
| PREGNANCY | Pregnancy category C | There are no adequate and well-controlled studies in pregnant women to inform drug-associated risk. |
| NOTE | |